Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| VRX | Valeant Pharmaceuticals International, Inc. | -0.07% | 30.24 | 14.1% | $177.94m | |
| HZNP | Horizon Therapeutics Plc | 0.00% | 91.45 | 5.5% | $174.64m | |
| GWPH | GW Pharmaceuticals Plc | 0.00% | 218.36 | 6.1% | $132.57m | |
| CTLT | Catalent, Inc. | 0.06% | 109.98 | 2.1% | $128.58m | |
| BHC | Bausch Health Cos., Inc. | -0.07% | 30.24 | 0.0% | $123.31m | |
| ICLR | ICON plc | 0.00% | 196.43 | 4.2% | $121.81m | |
| UTHR | United Therapeutics Corp. | 0.00% | 202.78 | 14.1% | $98.97m | |
| JAZZ | Jazz Pharmaceuticals Plc | 0.00% | 166.37 | 2.3% | $88.00m | |
| SAVA | Cassava Sciences, Inc. | 0.00% | 35.67 | 0.0% | $69.79m | |
| ARGX | argenx SE | 0.00% | 272.78 | 0.0% | $50.95m | |
| SAGE | SAGE Therapeutics, Inc. | 0.00% | 75.67 | 7.6% | $37.98m | |
| PRGO | Perrigo Co. Plc | 0.07% | 40.41 | 6.9% | $37.14m | |
| AMRN | Amarin Corp. Plc | 0.00% | 5.11 | 1.5% | $28.81m | |
| PCRX | Pacira Biosciences, Inc. | 0.00% | 69.43 | 9.9% | $26.96m | |
| ICPT | Intercept Pharmaceuticals, Inc. | 0.00% | 21.41 | 16.8% | $21.61m |
Company Profile
Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-Câ€) agonists.